Zimybe 10/10 New Zealand - English - Medsafe (Medicines Safety Authority)

zimybe 10/10

viatris limited - ezetimibe 10mg; simvastatin 10mg;   - tablet - 10mg/10mg - active: ezetimibe 10mg simvastatin 10mg   excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - primary hypercholesterolaemia zimybe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not adequately treated on a statin alone. homozygous familial hypercholesterolaemia (hofh) zimybe is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Zimybe 10/20 New Zealand - English - Medsafe (Medicines Safety Authority)

zimybe 10/20

viatris limited - ezetimibe 10mg; simvastatin 20mg;   - tablet - 10mg/20mg - active: ezetimibe 10mg simvastatin 20mg   excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - primary hypercholesterolaemia zimybe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not adequately treated on a statin alone. homozygous familial hypercholesterolaemia (hofh) zimybe is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Zimybe 10/40 New Zealand - English - Medsafe (Medicines Safety Authority)

zimybe 10/40

viatris limited - ezetimibe 10mg; simvastatin 40mg;   - tablet - 10mg/40mg - active: ezetimibe 10mg simvastatin 40mg   excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - primary hypercholesterolaemia zimybe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not adequately treated on a statin alone. homozygous familial hypercholesterolaemia (hofh) zimybe is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Zimybe 10/80 New Zealand - English - Medsafe (Medicines Safety Authority)

zimybe 10/80

viatris limited - ezetimibe 10mg; simvastatin 80mg;   - tablet - 10mg/80mg - active: ezetimibe 10mg simvastatin 80mg   excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - primary hypercholesterolaemia zimybe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not adequately treated on a statin alone. homozygous familial hypercholesterolaemia (hofh) zimybe is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

ETRICIB Tablets 90 mg Tanzania - English - Tanzania Medicinces & Medical Devices Authority

etricib tablets 90 mg

zim laboratories limited, india - etoricoxib - tablets - 90 mg

AZITO SUSPENSION Dry Powder for Suspension 200 Tanzania - English - Tanzania Medicinces & Medical Devices Authority

azito suspension dry powder for suspension 200

zim laboratories limited, india - azithromycin - dry powder for suspension - 200

Rozim-20 20mg tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

rozim-20 20mg tablets film-coated

zim laboratories ltd. - rosuvastatin (rosuvastatin calcium) - tablets film-coated - 20mg

Rozim-10 tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

rozim-10 tablets film-coated

zim laboratories ltd. - rosuvastatin (rosuvastatin calcium) - tablets film-coated - 10mg

Rozim-20 tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

rozim-20 tablets film-coated

zim laboratories ltd. - rosuvastatin (rosuvastatin calcium) - tablets film-coated - 20mg

EXAMETAZIME HMPAO- exametazime injection, powder, lyophilized, for solution United States - English - NLM (National Library of Medicine)

exametazime hmpao- exametazime injection, powder, lyophilized, for solution

anazaohealth corporation - exametazime (unii: g29272nckl) (exametazime - unii:g29272nckl) - exametazime 1 mg - exametazime is a diagnostic agent used as an adjunct in the detection of altered cerebral perfusion in stroke patients and is also indicated for white blood cell labeling as an adjunct in the localization of abdominal infections and inflammatory bowel disease there are no known contraindications for this preparation.